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TECHNICAL NOTE
A solid phase fluorescent immunoassay for the measurement
of human urinary albumin
BLANCHE M. CHAVERS, JAY SIM0Ns0N, and ALFRED F. MICHAEL
Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, Minnesota
Human urinary albumin excretion (UAE) has been measured
by radial immunodiffusion [1], nephelometry [2], and radio-
immunoassay (RIA) [3]. RIA measures nanogram quantities of
urinary albumin and, to our knowledge, is the most sensitive
available method for quantitating UAE not detectable by Albus-
tix. Recent studies argue that increased microalbuminuria in
patients with insulin-dependent diabetes may be predictive of
nephropathy risk [4, 5]. Because RIA poses potential health
hazards, requires expensive equipment, and is technically com-
plex, we evaluated a non-isotopic immunoassay to measure
UAE. This fluorescent immunoassay (FIA) resembles the RIA,
requiring specific antiserum and similar incubation and separa-
tion techniques [6]. The FIA is more sensitive than radial
immunodiffusion methods and has been shown to accurately
measure human albumin and immunoglobulin levels in saliva
[7]. Herein, we report our studies on the sensitivity, accuracy,
and reproducibility of the FIA for measuring UAE in normal
subjects.
Methods. Thirty-two healthy adults (14 females) hospitalized
for evaluation as potential kidney transplant donors served as
the subjects. Thus, BP, urinalysis, urine culture, serum creati-
nine, 24-hr urine collection for creatinine clearance, UAE, and
an intravenous pyelogram (IVP) were obtained on all subjects.
These subjects, ranging in age from 17 to 61 years (mean, 32.3
years), had normal BP (mean, 116/78 mm Hg), serum creatinine
levels (mean, 0.92 mg/dl), and normal creatinine clearances
(mean, 105 ml/min/1.73 m2). All other studies were within
normal limits. Serum albumin levels were measured in 22 of
these subjects and were normal (mean, 4.08 g/dl). Informed
consent was obtained from all participants. A 5-ml aliquot from
a measured 24-hr urine collection was preserved with 25 p1 of
2% sodium azide (NaN3) and stored at —20°C until evaluated.
Reagents. Immunobead reagent for antibody coupling was
obtained from Bio-Rad Laboratories, Richmond, California.
Both fluorescein isothiocyanate (FITC) conjugated and uncon-
jugated goat antisera to human albumin (GAHA) (IgG fraction)
were purchased from Cappel Laboratories, Cochranville, Penn-
sylvania. Chicken egg albumin grade V and human albumin
were obtained from Sigma Chemical Company, St. Louis,
Missouri. Lyophyllized immunobead matrix and antisera to
human albumin were reconstituted according to package in-
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structions and stored at 4°C and —20°C, respectively, until
used.
Immunobead preparation and coupling with antibody. Cova-
lent bonding of antibody to the immunobead matrix was carried
out according to Bio-Rad Laboratory instructions [8] with the
following modifications: GAHA (2 mg) was dialyzed for 4 hr
against 500 ml of couling buffer (0.003 M KH2PO4, pH 6.3) at
4°C. The dialyzed antibody was added to 200 mg of lyophillized
immunobead matrix, and the total volume of the preparation
was adjusted to 20 ml with sterile water and brought to pH 6.3
with 0.5 N HCI. Following incubation at 4°C for 1 hr, 40 mg of
ethyl dimethylaminopropyl carbodiimide (EDAC) were added
to the mixture to facilitate covalent bonding of the GAHA to the
beads. The mixture was brought to a pH of 6.3 at room
temperature and maintained at that pH for 30 mm with 0.5 N
HC1 and 1 N KOH. The mixture was then stored overnight at
4°C. Unbound material was removed by washing with buffers in
the following sequence: phosphate-buffered saline (PBS) (0,01
M KH2 PU4, 0,15 M NaCI, pH 7.2) times three; 1.4 M NaCl—
PBS twice; two additional washes in PBS, The immunobead
matrix was resuspended in 20 ml PBS and incubated at 4°C for 3
hr to allow renaturation of the covalently bound proteins. This
step was followed by two washes in 0.005 M KH2PO4, pH 7.2.
Each wash was followed by centrifugation at 2000 rpm for 10
mm, decanting of the supernatant, and resuspension of the
pellet in the appropriate buffer. A phosphate buffer (P0, 0.005
M phosphate—0.5% ovalbumin 0.1% NaN3) was used for the last
resuspension of the pellet. The immunobead reagent was then
stored at 4°C until used.
Preparation of human serum albumin (HSA) standards.
Lyophyllized HSA (2.5 mg) was solubilized in 25 ml of 0.005 M
P0 buffer to produce a 100,000 ng/ml standard. All other
standards were prepared from this stock solution.
Urinary albumin FIA procedure. All urine samples were
assayed at room temperature either undiluted or diluted 1:2 in
0.5% ovalbumin-PBS. All urine samples were negative for
albumin by Albustix® (Ames Division, Miles Laboratories,
Elkhart, Indiana), which became positive at an albumin level of
50,000 ng/ml. Urine samples that are positive by Albustix
should be diluted (trace — 1:10, + — 1:50, ++ — 1:100, +++ —
1:1000) prior to measuring the albumin level. The FIA is a
variation of methods previously described [6, 7]. The antibody
coupled immunobead reagent (100 p1) was added to borosilicate
tubes, followed by 20 p1 of either a standard or urine sample and
mixed by agitation on a vortex mixer. PBS (20 pi) was added to
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Fig. 2. Twenty-four hour urinary albumin excretion in control subjects.
Each closed circle represents one individual.
the blank tubes. After incubation at 37°C for 1.5 hr, 20 1 of 1%
ovalbumin-PBS, and 20 il of FITC GAHA (1:20 dilution with
1% ovalbumin in PBS buffer) were added to each tube followed
by mixing and incubation at 37°C for 2 hr. Samples were then
washed in PBS followed by centrifugation at 3000 rpm for 10
mm. This step was repeated twice. The remaining pellet was
resuspended in 2.0 ml PBS and the percent relative fluores-
cence (%RF) determined using a spectrofluorometer (Aminco-
Bowman American Instrument Company, Silver Springs,
Maryland) at an excitation wavelength of 485 nm and an
Specimen
number
Mean albumin
concentration
ng/ml SD
Coefficient of
variation
(%)a
1 7016 538 7.67
2 9898 674 6.81
3 6763 381 5.63
emission wavelength of 525 nm. The albumin concentration of
duplicate samples was calculated from a standard curve. Stan-
dard statistical formulae were used.
Results. The standard curve was linear in the range of 500 to
20,000 nglml of albumin with a correlation coefficient of 0.99
(Fig. 1). The standard curve was not linear at values above
20,000 ng/ml of albumin. The mean %RF of 32 samples of a 500
nglml standard assayed on 16 different days was 3.7% 0.67 (X
SD). The mean recovery of 2500 or 5000 nglml of albumin
standard added to 16 urine samples was 105% 7%. The
interassay coefficient of variation (CV) of ten samples of three
different unknown urine specimens measured on the same day
was 5.6 to 7.7% (Table 1). The intra-assay CV for 23 urine
samples (measuring between 700 and 19,900 nglml) each mea-
sured on 2 to 4 different days was 7.8%. Using range statistics,
we calculated the average difference between duplicates on 200
random samples. The allowable difference between duplicates
was 500 ng/ml [9]. The mean 24-hr UAE rate for the subjects
was 8.16 mg 5.24 (X sD; range, 1.33 to 20,50 mg) (Fig. 2).
There was no significant correlation between UAE and age (r =
—0.21), body surface area (r = —0.19) or creatinine clearance (r
= 0.23).
Discussion. This study demonstrates that the FIA is a sensi-
tive method for detecting human UAE in the normal concentra-
tion range. The inter- and intra-assay CV experiments demon-
strate the good precision of the assay at nanograms per milliliter
quantities. Recovery studies compare favorably to a recovery
of 103 9% reported in the ImmunoFluor® instruction manual
[10].
Urinary albumin has been measured previously by FIA
employing fluorescein labelling of the albumin antigen and
magnetizable particles to which antibodies to HSA are cova-
lently linked [11] or albumin labelled with fluorescein and
antibodies against both albumin and fluorescein [12]. However,
the calibration curves for these methods are nonlinear as
compared to the linear calibration curve in the method we
describe; these methods are relatively insensitive measuring 1.5
million to 100 million nglml and 4 million to 100 million nglml,
respectively. The method we have described in this report is a
minor modification of the method previously described by
Izutsu et al [7]. The major new observation is the application of
the method to urine, The lower limit of sensitivity of the FIA
method described by Izutsu et al [7] to measure salivary
albumin levels was 1000 ng/ml, similar to the lower limit of
sensitivity of 500 ng/ml with the method we have described.
The values of UAE in normal subjects obtained in this study
are very similar to these obtained by RIA. Viberti et al [13] and
Mogensen [14] report UAE in normal subjects to be 3.6 to 23
and 7.2 to 28.8 mg124 hr, respectively.
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Table 1. Coefficient of variation within-run analysis of ten samples of
three unknown urine specimens
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Fig. 1. Standard curve for human albumin. Each closed circle repre-
sents human albumin concentration.
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The FIA procedure for UAE is reproducible over a wide
range. The method is sensitive and precise and can also be
applied to urine samples containing high concentrations of
albumin. The assay can be performed in 4 to 6 hr. The low cost
and avoidance of isotopic reagents offer significant advantages
over the RIA.
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